Abstract |
To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.
|
Authors | K Linke, R Pazdur, J L Abbruzzese, J A Ajani, R Winn, J E Bradof, K Daugherty, B Levin |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 9
Issue 4
Pg. 353-6
(Nov 1991)
ISSN: 0167-6997 [Print] United States |
PMID | 1804812
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Imides
- Isoquinolines
- Naphthalimides
- Organophosphonates
- amonafide
- Adenine
|
Topics |
- Adenine
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Drug Evaluation
- Female
- Humans
- Imides
- Isoquinolines
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Naphthalimides
- Organophosphonates
- Pancreatic Neoplasms
(drug therapy)
|